Genfit S.A.

Paris Stock Exchange GNFT.PA

Genfit S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -17.65%

Genfit S.A. Return on Capital Employed (ROCE) is -17.65% for the year ending December 31, 2023, a -22.21% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Genfit S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -14.44%, a -198.25% change year over year.
Genfit S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 14.69%, a 125.68% change year over year.
Genfit S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -57.23%, a -170.88% change year over year.
Genfit S.A. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -21.13%, a 42.18% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Paris Stock Exchange: GNFT.PA

Genfit S.A.

CEO	Mr. M. Pascal Prigent
IPO Date	Dec. 19, 2006
Location	France
Headquarters	Parc EurasantE
Employees	169
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Key trends

Past 5 years